Last reviewed · How we verify
Short antibiotic treatment
This drug targets bacterial cell wall synthesis to inhibit bacterial growth.
This drug targets bacterial cell wall synthesis to inhibit bacterial growth. Used for Community-acquired pneumonia, Skin and soft tissue infections.
At a glance
| Generic name | Short antibiotic treatment |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antibiotic |
| Target | PBPs (Penicillin-binding proteins) |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
It achieves this by binding to the bacterial enzyme PBPs, which are essential for cell wall synthesis. This ultimately leads to the death of the bacterial cell.
Approved indications
- Community-acquired pneumonia
- Skin and soft tissue infections
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Comparing Two Root Canal Cleaning Solutions (Chlorhexidine vs. Sodium Hypochlorite) for Pain After Treatment (NA)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Safe and Explainable AI
- Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
- Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis (NA)
- Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Short antibiotic treatment CI brief — competitive landscape report
- Short antibiotic treatment updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI